The Food and Drug Administration on Monday approved a high-profile Alzheimer's drug, a controversial decision to green light the first new drug to slow the mind-robbing disease in nearly two decades.

Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio of two proteins, pTau217 and ß-Amyloid 1-42, which are implicated in ...

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

FDA approval comes after controversy over other Alzheimer's drug, Aduhelm The decision to approve lecanemab came after last week's scathing congressional report on high-profile Aduhelm.. In an 18 ...

The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults ...

The Food and Drug Administration on Friday approved an Alzheimer's drug, lecanemab, to be sold under the brand name Leqembi, which has modestly slowed cognitive decline in some people in the early ...

An experimental Alzheimer’s drug, donanemab, was endorsed by a U.S. Food and Drug Administration (FDA) advisory panel on Monday. Donanemab is designed to treat symptoms of early Alzheimer’s ...

After months of anticipation, US Food and Drug administration has finally granted traditional approval to Lecanemab, a drug that's been shown to significantly slow the progression of Alzheimer's.

The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease – despite an FDA advisory committee concluding last ...

A new, breakthrough drug designed to aggressively treat Alzheimer’s disease was awarded accelerated approval by the Food and Drug Administration on Friday.. Leqembi — developed by Tokyo ...

A panel of experts who advise the U.S. Food and Drug Administration (FDA) agreed on June 9 that a late-stage study of a drug for Alzheimer’s disease showed that it was beneficial in slowing ...

The drug, to be marketed by Biogen Inc. under the brand name Aduhelm, reduces the amyloid beta plaques that build up in the brains of people with Alzheimer’s.